Insider Selling: RxSight, Inc. (NASDAQ:RXST) Insider Sells 3,100 Shares of Stock

RxSight, Inc. (NASDAQ:RXSTGet Free Report) insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $45.00, for a total value of $139,500.00. Following the completion of the transaction, the insider now directly owns 42,246 shares in the company, valued at approximately $1,901,070. This represents a 6.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

  • On Tuesday, November 26th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $45.88, for a total transaction of $142,228.00.
  • On Friday, November 15th, Ilya Goldshleger sold 4,875 shares of RxSight stock. The shares were sold at an average price of $46.00, for a total transaction of $224,250.00.
  • On Monday, November 18th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $45.00, for a total transaction of $139,500.00.
  • On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The shares were sold at an average price of $46.13, for a total transaction of $61,352.90.
  • On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $51.91, for a total value of $161,180.55.
  • On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total value of $154,349.00.
  • On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.64, for a total value of $156,984.00.
  • On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.68, for a total value of $154,008.00.
  • On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total transaction of $155,529.45.
  • On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.78, for a total transaction of $154,318.00.

RxSight Trading Up 0.7 %

NASDAQ:RXST opened at $46.40 on Thursday. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -55.78 and a beta of 1.19. RxSight, Inc. has a twelve month low of $28.88 and a twelve month high of $66.54. The stock has a fifty day simple moving average of $49.00 and a 200-day simple moving average of $52.48.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. CWM LLC boosted its holdings in shares of RxSight by 727.5% in the second quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after purchasing an additional 371 shares during the period. Nisa Investment Advisors LLC raised its stake in RxSight by 854.1% in the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after buying an additional 521 shares in the last quarter. Quarry LP lifted its holdings in RxSight by 82.3% during the third quarter. Quarry LP now owns 638 shares of the company’s stock worth $32,000 after buying an additional 288 shares during the period. Point72 Hong Kong Ltd bought a new stake in RxSight during the 3rd quarter valued at $34,000. Finally, Quest Partners LLC purchased a new position in shares of RxSight in the 2nd quarter valued at $41,000. Hedge funds and other institutional investors own 78.78% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on RXST shares. Oppenheimer lowered their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Jefferies Financial Group assumed coverage on RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Stifel Nicolaus decreased their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Finally, Wells Fargo & Company dropped their price objective on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $61.63.

Read Our Latest Research Report on RxSight

RxSight Company Profile

(Get Free Report)

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

See Also

Insider Buying and Selling by Quarter for RxSight (NASDAQ:RXST)

Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.